Histone deacetylase inhibitors in oral squamous cell carcinoma treatment

Bibliography

• Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 2009;45:309-16
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108
   PubMed Web of Science ®Google Scholar
• Scully C, Bagan J. Oral squamous cell carcinoma overview. Oral Oncol 2009;45:301-8
   PubMed Web of Science ®Google Scholar
• Brenner H. Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis. Lancet 2002;360:1131-5
   PubMed Web of Science ®Google Scholar
• Barnes L, Eveson JW, Reichart P, Sidransky D. Pathology and genetics of head and neck tumours, World Health Organization classification of tumours. IARC Press, Lyon; 2005
   Google Scholar
• Brennan JA, Boyle JO, Koch WM, et al. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med 1995;332:712-17
   PubMed Web of Science ®Google Scholar
• Wang XI, Thomas J, Zhang S. Changing trends in human papillomavirus–associated head and neck squamous cell carcinoma. Ann Diagn Pathol 2012;16:7-12
   PubMed Web of Science ®Google Scholar
• Shillitoe EJ. The role of viruses in squamous cell carcinoma of the oropharyngeal mucosa. Oral Oncol 2009;45:351-5
   PubMed Web of Science ®Google Scholar
• Guha N, Boffetta P, Wünsch Filho V, et al. Oral health and risk of squamous cell carcinoma of the head and neck and esophagus: results of two multicentric case-control studies. Am J Epidemiol 2007;15:1159-73
   Google Scholar
• Shah JP, Gil Z. Current concepts in management of oral cancer–surgery. Oral Oncol 2009;45:394-401
   PubMed Web of Science ®Google Scholar
• Mazeron R, Tao Y, Lusinchi A, Bourhis J. Current concepts of management in radiotherapy for head and neck squamous-cell cancer. Oral Oncol 2009;45:402-8
   PubMed Web of Science ®Google Scholar
• Qiu T, Zhou L, Zhu W, et al. Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials. Future Oncol 2013;9:255-69
   PubMed Web of Science ®Google Scholar
• Glass E, Viale PH. Histone deacetylase inhibitors: novel agents in cancer treatment. Clin J Oncol Nurs 2013;17:34-40
   PubMed Web of Science ®Google Scholar
• Koutsounas I, Giaginis C, Theocharis S. Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials? World J Gastroenterol 2013;19:1173-81
   PubMed Web of Science ®Google Scholar
• Katafygiotis P, Giaginis C, Patsouris E, Theocharis S. Histone deacetylase inhibitors as potential therapeutic agents for the treatment of malignant mesothelioma. Anticancer Agents Med Chem 2013;13:476-82
   PubMed Web of Science ®Google Scholar
• Rangwala S, Zhang C, Duvic M. HDAC inhibitors for the treatment of cutaneous T-cell lymphomas. Future Med Chem 2012;4:471-86
   PubMedGoogle Scholar
• Wolffe AP, Pruss D. Deviant nucleosomes: the functional specialization of chromatin. Trends Genet 1996;12:58-62
   PubMed Web of Science ®Google Scholar
• Marks PA, Richon VM, Miller T, Kelly WK. Histone deacetylase inhibitors. Adv Cancer Res 2004;91:137-68
   PubMed Web of Science ®Google Scholar
• Battistini F, Hunter CA, Gardiner EJ, Packer MJ. Structural mechanics of DNA wrapping in the nucleosome. J Mol Biol 2010;396:264-79
   PubMed Web of Science ®Google Scholar
• Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene 2005;363:15-23
   PubMed Web of Science ®Google Scholar
• OMIM- Online Mendelian Inheritance in Man, McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD. Available from: http://www.omim.org/
   Google Scholar
• New M, Olzscha H, La Thangue NB. HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol 2012;6:637-56
   PubMed Web of Science ®Google Scholar
• Glaser KB, Li J, Staver MJ, et al. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem Biophys Res Commun 2003;310:529-36
   PubMed Web of Science ®Google Scholar
• Méjat A, Ramond F, Bassel-Duby R, et al. Histone deacetylase 9 couples neuronal activity to muscle chromatin acetylation and gene expression. Nat Neurosci 2005;8:313-21
   PubMed Web of Science ®Google Scholar
• Waterborg JH. Dynamics of histone acetylation in vivo. A function for acetylation turnover? Biochem Cell Biol 2002;80:363-78
   PubMed Web of Science ®Google Scholar
• Glaser KB, Staver MJ, Waring JF, et al. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2003;2:151-63
   PubMed Web of Science ®Google Scholar
• Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene 2007;26:5420-32
   PubMed Web of Science ®Google Scholar
• Tan J, Cang S, Ma Y, et al. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 2010;3:5
   PubMed Web of Science ®Google Scholar
• Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett 2009;280:168-76
   PubMed Web of Science ®Google Scholar
• Weichert W, Röske A, Niesporek S, et al. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res 2008;14:1669-77
   PubMed Web of Science ®Google Scholar
• Müller BM, Jana L, Kasajima A, et al. Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer–overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression. BMC Cancer 2013;13:215
   PubMed Web of Science ®Google Scholar
• Quint K, Agaimy A, Di Fazio P, et al. Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC. Virchows Arch 2011;459:129-39
   PubMed Web of Science ®Google Scholar
• Minamiya Y, Ono T, Saito H, et al. Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung. Lung Cancer 2011;74:300-4
   PubMed Web of Science ®Google Scholar
• Langer R, Mutze K, Becker K, et al. Expression of class I histone deacetylases (HDAC1 and HDAC2) in oesophageal adenocarcinomas: an immunohistochemical study. J Clin Pathol 2010;63:994-8
   Google Scholar
• Weichert W, Denkert C, Noske A, et al. Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia 2008;10:1021-7
   PubMed Web of Science ®Google Scholar
• Weichert W, Röske A, Gekeler V, et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 2008;98:604-10
   PubMed Web of Science ®Google Scholar
• Giaginis C, Alexandrou P, Delladetsima I, et al. Clinical significance of histone deacetylase (HDAC)-1, HDAC-2, HDAC-4, and HDAC-6 expression in human malignant and benign thyroid lesions. Tumour Biol 2014;35:61-71
   PubMed Web of Science ®Google Scholar
• Oehme I, Deubzer HE, Wegener D, et al. Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res 2009;15:91-9
   PubMed Web of Science ®Google Scholar
• Duong V, Bret C, Altucci L, et al. Specific activity of class II histone deacetylases in human breast cancer cells. Mol Cancer Res 2008;6:1908-19
   PubMed Web of Science ®Google Scholar
• Park SW, Kim HS, Yoo NJ, Lee SH. Mutational analysis of mononucleotide repeats in HDAC4, 5, 6, 7, 9 and 11 genes in gastric and colorectal carcinomas with microsatellite instability. Acta Oncol 2011;50:317-18
   PubMed Web of Science ®Google Scholar
• Moreno DA, Scrideli CA, Cortez MA, et al. Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia. Br J Haematol 2010;150:665-73
   PubMed Web of Science ®Google Scholar
• Milde T, Oehme I, Korshunov A, et al. HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth. Clin Cancer Res 2010;16:3240-52
   PubMed Web of Science ®Google Scholar
• Park BL, Kim YJ, Cheong HS, et al. HDAC10 promoter polymorphism associated with development of HCC among chronic HBV patients. Biochem Biophys Res Commun 2007;363:776-81
   PubMed Web of Science ®Google Scholar
• Zhang Z, Yamashita H, Toyama T, et al. HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res 2004;10:6962-8
   PubMed Web of Science ®Google Scholar
• Ramsey MR, He L, Forster N, et al. Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma. Cancer Res 2011;71:4373-9
   PubMed Web of Science ®Google Scholar
• Chang CC, Lin BR, Chen ST, et al. HDAC2 promotes cell migration/invasion abilities through HIF-1alpha stabilization in human oral squamous cell carcinoma. J Oral Pathol Med 2011;40:567-75
   PubMed Web of Science ®Google Scholar
• Sakuma T, Uzawa K, Onda T, et al. Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma. Int J Oncol 2006;29:117-24
   PubMed Web of Science ®Google Scholar
• Chang HH, Chiang CP, Hung HC, et al. Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients. Oral Oncol 2009;45:610-14
   PubMed Web of Science ®Google Scholar
• Theocharis S, Klijanienko J, Giaginis C, et al. Histone deacetylase-1 and -2 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival. J Oral Pathol Med 2011;40:706-14
   PubMed Web of Science ®Google Scholar
• Noguchi A, Li X, Kubota A, et al. SIRT1 expression is associated with good prognosis for head and neck squamous cell carcinoma patients. Oral Surg Oral Med Oral Pathol Oral Radiol 2013;115:385-92
   Web of Science ®Google Scholar
• Miller CP, Singh MM, Rivera-Del Valle N, et al. Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors. J Biomed Biotechnol 2011;2011:514261
   PubMedGoogle Scholar
• Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 2003;4:13-18
   PubMed Web of Science ®Google Scholar
• Hu J, Colburn NH. Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-kappaB/p65 DNA binding. Mol Cancer Res 2005;3:100-9
   PubMed Web of Science ®Google Scholar
• Yu D, Hung MC. Role of erbB2 in breast cancer chemosensitivity. Bioessays 2000;22:673-80
   PubMed Web of Science ®Google Scholar
• Scott GK, Marden C, Xu F, et al. Transcriptional repression of ErbB2 by histone deacetylase inhibitors detected by a genomically integrated ErbB2 promoter-reporting cell screen. Mol Cancer Ther 2002;1:385-92
   PubMed Web of Science ®Google Scholar
• Bruzzese F, Leone A, Rocco M, et al. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J Cell Physiol 2011;226:2378-90
   PubMed Web of Science ®Google Scholar
• Suzuki M, Endo M, Shinohara F, et al. Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells. Cancer Chemother Pharmacol 2009;64:1115-22
   PubMed Web of Science ®Google Scholar
• Shen J, Huang C, Jiang L, et al. Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines. Biochem Pharmacol 2007;73:1901-9
   PubMed Web of Science ®Google Scholar
• De Schutter H, Kimpe M, Isebaert S, Nuyts S. A systematic assessment of radiation dose enhancement by 5-Aza-2’-deoxycytidine and histone deacetylase inhibitors in head-and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2009;73:904-12
   PubMed Web of Science ®Google Scholar
• Eriksson I, Joosten M, Roberg K, Ollinger K. The histone deacetylase inhibitor trichostatin A reduces lysosomal pH and enhances cisplatin-induced apoptosis. Exp Cell Res 2013;319:12-20
   PubMed Web of Science ®Google Scholar
• Prystowsky MB, Adomako A, Smith RV, et al. The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines. J Pathol 2009;218:467-77
   PubMed Web of Science ®Google Scholar
• Chikamatsu K, Ishii H, Murata T, et al. Alteration of cancer stem cell-like phenotype by histone deacetylase inhibitors in squamous cell carcinoma of the head and neck. Cancer Sci 2013;104:1468-75
   PubMed Web of Science ®Google Scholar
• Giudice FS, Pinto DSJr, Nör JE, et al. Inhibition of histone deacetylase impacts cancer stem cells and induces epithelial-mesenchyme transition of head and neck cancer. PLoS One 2013;8:e58672
   PubMedGoogle Scholar
• Haigentz MJr, Kim M, Sarta C, et al. Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer. Oral Oncol 2012;48:1281-8
   PubMed Web of Science ®Google Scholar
• Zhang Z, Stanfield J, Frenkel E, et al. Enhanced therapeutic effect on androgen-independent prostate cancer by depsipeptide (FK228), a histone deacetylase inhibitor, in combination with docetaxel. Urology 2007;70:396-401
   PubMed Web of Science ®Google Scholar
• Hoshino I, Matsubara H, Akutsu Y, et al. Role of histone deacetylase inhibitor in adenovirus-mediated p53 gene therapy in esophageal cancer. Anticancer Res 2008;28:665-71
   PubMed Web of Science ®Google Scholar
• Han JW, Ahn SH, Park SH, et al. Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Res 2000;60:6068-74
   PubMed Web of Science ®Google Scholar
• Ahn MY, Ahn SG, Yoon JH. Apicidin, a histone deaceylase inhibitor, induces both apoptosis and autophagy in human oral squamous carcinoma cells. Oral Oncol 2011;47:1032-8
   Google Scholar
• Sato T, Suzuki M, Sato Y, et al. Sequence-dependent interaction between cisplatin and histone deacetylase inhibitors in human oral squamous cell carcinoma cells. Int J Oncol 2006;28:1233-41
   PubMed Web of Science ®Google Scholar
• Shoji M, Ninomiya I, Makino I, et al. Valproic acid, a histone deacetylase inhibitor, enhances radiosensitivity in esophageal squamous cell carcinoma. Int J Oncol 2012;40:2140-6
   PubMed Web of Science ®Google Scholar
• Gan CP, Hamid S, Hor SY, et al. Valproic acid: growth inhibition of head and neck cancer by induction of terminal differentiation and senescence. Head Neck 2012;34:344-53
   PubMed Web of Science ®Google Scholar
• Kothari V, Joshi G, Nama S, et al. HDAC inhibitor valproic acid enhances tumor cell kill in adenovirus-HSVtk mediated suicide gene therapy in HNSCC xenograft mouse model. Int J Cancer 2010;126:733-42
   PubMed Web of Science ®Google Scholar
• Gong L, Wang WM, Ji Y, et al. Effects of sodium butyrate on proliferation of human oral squamous carcinoma cell line and expression of p27Kip1. Zhonghua Kou Qiang Yi Xue Za Zhi 2010;45:619-22
   PubMedGoogle Scholar
• Bai LY, Chiu CF, Pan SL, et al. Antitumor activity of a novel histone deacetylase inhibitor (S)-HDAC42 in oral squamous cell carcinoma. Oral Oncol 2011;47:1127-33
   PubMed Web of Science ®Google Scholar